EMA confirms that hydroxyethyl starch solutions should not be used in critically ill, sepsis, or burns patientsBMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f6197 (Published 14 October 2013) Cite this as: BMJ 2013;347:f6197
- Susan Mayor
Hydroxethyl starch solutions (HES) should not be used for fluid replacement in critically ill patients or those with sepsis or burn injuries, ruled the European Medicines Agency (EMA) on 11 October after reviewing evidence showing increased risk of death or kidney injury.1
But the agency says these commonly used plasma substitutes can be used to treat patients with low blood volume caused by acute blood loss where treatment with a crystalloid infusion solution alone is not sufficient. Potential risks should be minimised by using HES solutions …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial